NovoCure Limited

NasdaqGS:NVCR Stok Raporu

Piyasa değeri: US$1.8b

NovoCure Yönetim

Yönetim kriter kontrolleri 4/4

NovoCure CEO'su Asaf Danziger, Jan2002 tarihinde atandı, in görev süresi 22.83 yıldır. in toplam yıllık tazminatı $ 1.52M olup, şirket hissesi ve opsiyonları dahil olmak üzere 49.7% maaş ve 50.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.014% ine doğrudan sahiptir ve bu hisseler $ 256.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 7 yıldır.

Anahtar bilgiler

Asaf Danziger

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi49.7%
CEO görev süresi22.8yrs
CEO sahipliği0.01%
Yönetim ortalama görev süresi2.6yrs
Yönetim Kurulu ortalama görev süresi7yrs

Son yönetim güncellemeleri

Recent updates

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Nov 01
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Oct 17
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

NovoCure: There Is Still More Upside

Oct 16

NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM

Oct 09

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Sep 12
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

NovoCure Limited: A Post Q2 Analysis

Jul 26

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

CEO Tazminat Analizi

Asaf Danziger'un ücretlendirmesi NovoCure'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$150m

Jun 30 2024n/an/a

-US$169m

Mar 31 2024n/an/a

-US$193m

Dec 31 2023US$2mUS$756k

-US$207m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$174m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$831k

-US$93m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$876k

-US$58m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

US$12m

Dec 31 2020US$9mUS$782k

US$20m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$12m

Mar 31 2020n/an/a

US$9m

Dec 31 2019US$7mUS$702k

-US$7m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$41m

Mar 31 2019n/an/a

-US$55m

Dec 31 2018US$5mUS$693k

-US$64m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$59m

Mar 31 2018n/an/a

-US$64m

Dec 31 2017US$4mUS$698k

-US$62m

Tazminat ve Piyasa: Asaf 'nin toplam tazminatı ($USD 1.52M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.37M ).

Tazminat ve Kazançlar: Asaf 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Asaf Danziger (58 yo)

22.8yrs

Görev süresi

US$1,521,026

Tazminat

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
William Doyle
Executive Chairman20.8yrsUS$1.43m0.51%
$ 9.3m
Asaf Danziger
CEO & Director22.8yrsUS$1.52m0.014%
$ 256.7k
Ashley Cordova
Chief Financial Officer4.2yrsUS$6.32m0.085%
$ 1.5m
Barak Arye
General Counsel2.6yrsUS$4.86m0.019%
$ 355.0k
Frank Leonard
Executive VP & President of Novocure Oncology4.2yrsUS$5.04m0.047%
$ 856.7k
Yoram Palti
Founder & CTO24.8yrsUS$282.51kVeri yok
Mukund Paravasthu
Chief Operating Officerless than a yearVeri yok0.0032%
$ 58.4k
Ingrid Goldberg
VP of Investor Relationsno dataVeri yokVeri yok
Michael Puri
Chief Human Resources Officer1.2yrsVeri yok0.012%
$ 226.9k
Uri Weinberg
Chief Innovation Officer1.8yrsVeri yok0.057%
$ 1.0m
Piet Hinoul
Senior VPno dataVeri yokVeri yok
Nicolas Leupin
Chief Medical Officerless than a yearVeri yokVeri yok

2.6yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: NVCR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
William Doyle
Executive Chairman20.8yrsUS$1.43m0.51%
$ 9.3m
Asaf Danziger
CEO & Director12.8yrsUS$1.52m0.014%
$ 256.7k
Jeryl Hilleman
Independent Director6.3yrsUS$446.09k0.0023%
$ 42.7k
David Hung
Independent Director6.5yrsUS$426.09k0.0084%
$ 154.2k
Timothy Scannell
Independent Director3.8yrsUS$448.53k0.0036%
$ 66.2k
Kinyip Leung
Independent Director13.1yrsUS$435.53k0.073%
$ 1.3m
William Vernon
Lead Independent Director18.8yrsUS$475.53k0.15%
$ 2.7m
Martin Madden
Independent Director7.5yrsUS$446.09k0.014%
$ 263.4k
Kristin Stafford
Independent Director1.7yrsUS$696.94k0%
$ 0
Allyson Ocean
Independent Director1.8yrsUS$697.26k0%
$ 0

7.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NVCR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).